Infectious Disease Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: June 16, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 41.34 billion |
|
Revenue Forecast in 2031 |
US$ 82.52 billion |
|
CAGR |
7.45% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Indication, Drug Class, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global infectious disease therapeutics market was valued at US$ 41.34 billion in 2022 and is expected to register a revenue CAGR of 7.45% to reach US$ 82.52 billion by 2031.
Infectious Disease Therapeutics Market Fundamentals
Infectious diseases are caused by microorganisms such as bacteria, viruses, fungi, or parasites. These pathogens can invade the body and disrupt normal functions, leading to various symptoms and health complications. Infectious diseases can be transmitted from person to person through contact with contaminated objects or surfaces or through vectors such as mosquitoes or ticks. Some infectious diseases include Influenza, tuberculosis (TB), malaria, HIV/AIDS, hepatitis, and others.
Infectious Disease Therapeutics Market Dynamics
The rising incidence of infectious diseases worldwide is a significant driver for the infectious disease therapeutics market. According to a WHO report, it was recorded that a total of 10.6 million people suffered from tuberculosis in 2021, which is equivalent to 134 cases per 100 000 population. Geographically, most of the tuberculosis cases in 2021 were found in South-East Asia (45%), Africa (23%), and the Western Pacific (18%), with smaller shares in the Eastern Mediterranean (8.1%), the Americas (2.9%) and Europe (2.2%). Factors such as population growth, urbanization, travel, and changing lifestyles contribute to the spread of infectious diseases, creating a greater demand for effective therapeutics. The emergence or re-emergence of infectious diseases, such as the COVID-19 pandemic, Ebola outbreaks, and Zika virus infections, has highlighted the need for robust therapeutics to combat these diseases. According to WHO report, globally, as of June 2023, nearly 767,984,989 confirmed cases of COVID-19, including 6,943,390 deaths, are reported to WHO. The market responds to such outbreaks with increased investments in research and development (R&D) for new and improved therapies.
The growing problem of antimicrobial resistance (AMR), where microorganisms develop resistance to existing antimicrobial drugs, has created a need for new therapeutics to combat drug-resistant infections. This drives the development of novel antibiotics, antivirals, and antifungal drugs to overcome resistance mechanisms. Advances in biotechnology, genomics, and drug discovery technologies have led to identifying new drug targets and developing innovative therapies. These advancements enable the discovery of more effective and targeted treatments for infectious diseases. Governments, pharmaceutical companies, and research institutions are investing significantly in R&D activities focused on infectious diseases. These investments drive the development of new therapeutics and contribute to market growth. The development and use of vaccines for infectious diseases play a vital role in disease prevention and control. Furthermore, immunotherapies, such as monoclonal antibodies or immune checkpoint inhibitors, are being explored as treatment options for certain infectious diseases, further driving the market. Rising healthcare expenditure, particularly in developing countries, provides the necessary resources to invest in infectious disease therapeutics. Improved access to healthcare services and increased affordability of treatments positively impacts market growth.
However, developing new therapeutics, particularly antimicrobial drugs, involves significant costs, including preclinical and clinical trials. The lengthy and expensive drug development process poses financial challenges, especially for smaller pharmaceutical companies and research institutions, limiting their ability to bring new treatments to market. Some infectious diseases primarily affect low-income or developing regions where the ability to pay for expensive treatments may be limited. This can deter pharmaceutical companies from investing in research and development for these diseases, leading to a lack of effective therapeutics for specific infectious diseases. While vaccines play a crucial role in preventing infectious diseases, there are still several diseases for which vaccines are not available or are not highly effective. Inadequate preventive measures can contribute to the persistence and spread of infectious diseases, requiring a greater focus on therapeutic interventions. Infectious diseases disproportionately affect populations in low-income countries or regions with limited access to healthcare resources. The lack of infrastructure, healthcare systems, and diagnostic capabilities in these areas hinders the effective treatment and control of infectious diseases. The shortage of skilled healthcare professionals, including infectious disease specialists, in many regions, poses a challenge to the timely diagnosis, management, and treatment of infectious diseases. This can lead to delays in appropriate therapies and adversely impact patient outcomes.
Infectious Disease Therapeutics Market Ecosystem
The global infectious disease therapeutics market has been analyzed from the following perspectives: by indication, drug class, distribution channel, and region.
Infectious Disease Therapeutics Market by Indication
Based on the indication, the global infectious disease therapeutics market is segmented into tuberculosis, influenza, HIV/AIDS, hepatitis, and others
The influenza segment accounted for a sizeable revenue share in the global market in 2022. Influenza is characterized by annual seasonal outbreaks, affecting a significant portion of the population worldwide. These outbreaks result in a substantial number of cases seeking medical attention and treatment, driving the demand for influenza therapeutics. For instance, according to the report by ‘Our World in Data’, it was estimated that the seasonal flu, a contagious illness caused by the influenza virus, kills around 400,000 people from the respiratory disease annually. The high transmission rate leads to a large number of individuals seeking medical care and increases the need for therapeutics to manage and treat the disease. Influenza can affect individuals of all age groups, from young children to the elderly. The disease can cause severe illness, hospitalization, and even death, particularly among vulnerable populations such as the elderly, young children, pregnant women, and individuals with underlying health conditions. The broad demographic affected by influenza contributes to the demand for therapeutics. Influenza outbreaks have a significant economic impact due to the loss of productivity, increased healthcare utilization, and the associated costs of treating the disease. Governments, healthcare organizations, and individuals invest in influenza therapeutics to mitigate these economic burdens. Influenza viruses can undergo frequent antigenic changes through genetic mutations and reassortment, resulting in the emergence of new strains. This antigenic variability necessitates the development of new influenza therapeutics, including updated vaccines, antiviral drugs, and other treatments to target the evolving strains effectively. Influenza can lead to severe complications, especially in high-risk individuals. Therefore, prevention through vaccination and prompt treatment with antiviral medications is essential to reduce the severity and duration of the illness. The emphasis on prevention and early intervention drives the demand for influenza therapeutics. Influenza has been the subject of extensive research, with a long history of vaccine development and antiviral drug discovery. The established market and ongoing research activities in influenza therapeutics contribute to its dominance in the global infectious disease therapeutics market.
Infectious Disease Therapeutics Market by Drug Class
Based on the drug class, the global infectious disease therapeutics market is segmented into antiviral, antibacterial, antiparasitic, antifungal, and others.
The bacterial infections segment accounted for a significant revenue share in the global market in 2022. Bacterial infections are one of the most common types of infectious diseases globally. They can affect various body systems and cause a wide range of illnesses, including respiratory infections, urinary tract infections, skin infections, gastrointestinal infections, and bloodstream infections. The high prevalence of bacterial infections drives the demand for antibacterial therapeutics. According to ‘ReAct’ 2022 Report, it was estimated that 7.7 million deaths across the globe were recorded linked to bacterial infection, which is nearly 13.6%, or 1 in 8, of all global deaths. Antibacterial drugs have a broad spectrum of activity, meaning they can target and treat a wide range of bacterial pathogens. This versatility makes them essential in treating various bacterial infections, including community-acquired and healthcare-associated infections. Chronic infections, such as tuberculosis or bacterial meningitis, require long-term antimicrobial therapy to cure or control the infection. Antibacterial drugs are routinely used in surgical settings for prophylaxis to prevent surgical site infections. They are administered before surgical procedures to reduce the risk of bacterial contamination and subsequent infections, enhancing patient safety. Hospital-acquired infections, including those caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant Gram-negative bacteria, pose a significant challenge in healthcare settings.
Infectious Disease Therapeutics Market by Distribution Channel
Based on the distribution channel, the global infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Retail pharmacies account for a sizeable revenue share in the global market. Retail pharmacies are often conveniently located within communities, making them easily accessible to the general population. Retail pharmacies are the primary point for dispensing prescribed infectious disease therapeutics to patients. They play a crucial role in ensuring that patients receive the correct medications, appropriate dosages, and clear instructions for use. Pharmacists also provide counseling and guidance to patients regarding their prescribed medications. Retail pharmacies often engage in patient education initiatives, including raising awareness about infectious diseases, preventive measures, and the importance of adherence to prescribed medications. They can provide valuable information on proper medication usage, potential side effects, and drug interactions, enhancing patient understanding and compliance. Many retail pharmacy chains have established partnerships with healthcare systems and medical providers, enabling efficient communication and coordination in prescribing and dispensing infectious disease therapeutics. This integration facilitates a streamlined process for patients and healthcare professionals involved in infectious disease management.
Infectious Disease Therapeutics Market by Region
Based on the region, the global infectious disease therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global market with 41.6% of the revenue share in 2022. North America has a highly developed healthcare infrastructure, including robust healthcare systems, advanced medical facilities, and well-established regulatory frameworks. This infrastructure enables efficient research, development, and delivery of infectious disease therapeutics. North America has one of the highest healthcare expenditures globally, with significant investments in healthcare infrastructure, research and development, and access to healthcare services. This financial commitment allows for greater investment in infectious disease therapeutics and the adoption of innovative treatments. North America houses several leading pharmaceutical companies and biotechnology firms that are actively involved in the research, development, and commercialization of infectious disease therapeutics. These companies have the resources, expertise, and infrastructure to drive innovation and dominate the market. North America has a strong research and development ecosystem with renowned academic institutions, research centers, and biotechnology clusters. The region's emphasis on scientific research and collaborations contribute to advancements in infectious disease therapeutics. North America faces a substantial burden of infectious diseases, including respiratory infections, sexually transmitted infections, vector-borne diseases, and healthcare-associated infections. According to the ‘CDC report,’ it was estimated that in 2022, 8,300 tuberculosis cases were recorded in the United States, compared with 7,874 cases reported in 2021. Thus, the tuberculosis incidence showed a rising trend in 2022 (2.5 cases per 100,000 persons). This disease burden drives the demand for effective therapeutics and contributes to the dominance of the market.
Infectious Disease Therapeutics Market Competitive Landscape
The prominent players operating in the global infectious disease therapeutics market are:
Infectious Disease Therapeutics Market Strategic Developments
Infectious diseases are caused by microorganisms such as bacteria, viruses, fungi, or parasites. These pathogens can invade the body and disrupt its normal functions, leading to a wide range of symptoms and health complications.
AbbVie Inc., Novartis AG, Sanofi SA, and F. Hoffmann-La Roche Ltd. are some of the major market players in the global infectious disease therapeutics market.
The high cost of drug development and limited profitability for infectious disease therapeutics are some of the restraints obstructing the growth of the global market.
The hospital pharmacies segment dominated the global infectious disease therapeutics market in 2022
The high prevalence of infectious diseases and technological advancements and drug innovation are some of the major factors driving the global market.
*Insights on financial performance are subject to the availability of information in the public domain